Skip to content
CancerIndex

Publication

Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer.

Mehmet Haluk Yucel, Maral Martin Mildanoglu, Ebru Engin Delipoyraz, Hakan Ozcelik, Erdem Sunger, Sena Fidan, Cihat Terzioglu, Tansel Cakir, Harun Muglu, Burcin Cakan Demirel, Jamshid Hamdard, Yasin Kutlu, Ozgur Acıkgoz, Mesut Seker, Ahmet Bilici

OncoimmunologyDec 31, 2026PMID 42788839doi:10.1080/2162402X.2026.2738262 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 29, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260929-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Growing evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors across multiple malignancies. However, evidence in extensive-stage small cell lung cancer (ES-SCLC) remains limited to a single East Asian cohort, and independent validation in other populations…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.